Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Clinical Trial Evaluating the Safety Efficacy of Fc-Modified Anti-CD154 mAB (TNX-1500) in Kidney Transplant Recipients

NCT07204080 is registered in ClinicalTrials.gov with Ayman Al Jurdi, MD as lead sponsor.

NCT NCT07204080
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07204080 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Clinical Trial Evaluating the Safety Efficacy of Fc-Modified Anti-CD154 mAB (TNX-1500) in Kidney Transplant Recipients
Lead sponsor
Ayman Al Jurdi, MD
Phase
Phase 2
Overall status
Not yet recruiting
Start date
November 1, 2026
Completion date
November 30, 2029
Enrollment
5 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

immunosuppression, immunosuppression after kidney transplantation, kidney transplant, kidney transplant failure and rejection